WO2012088247A3 - Fragments et anticorps anti-c5/c5a/c5adesr - Google Patents

Fragments et anticorps anti-c5/c5a/c5adesr Download PDF

Info

Publication number
WO2012088247A3
WO2012088247A3 PCT/US2011/066437 US2011066437W WO2012088247A3 WO 2012088247 A3 WO2012088247 A3 WO 2012088247A3 US 2011066437 W US2011066437 W US 2011066437W WO 2012088247 A3 WO2012088247 A3 WO 2012088247A3
Authority
WO
WIPO (PCT)
Prior art keywords
c5adesr
polypeptide
antibodies
antigen
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/066437
Other languages
English (en)
Other versions
WO2012088247A2 (fr
Inventor
Caroline COLLEY
Claire Dobson
Joanne BRENNAN
Sek Fung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to CA2822288A priority Critical patent/CA2822288A1/fr
Publication of WO2012088247A2 publication Critical patent/WO2012088247A2/fr
Publication of WO2012088247A3 publication Critical patent/WO2012088247A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions, des procédés de fabrication et des procédés d'utilisation se rapportant à des anticorps anti-C5/C5a/C5adesR et à des fragments de liaison à l'antigène.
PCT/US2011/066437 2010-12-22 2011-12-21 Fragments et anticorps anti-c5/c5a/c5adesr Ceased WO2012088247A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2822288A CA2822288A1 (fr) 2010-12-22 2011-12-21 Fragments et anticorps anti-c5/c5a/c5adesr

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061426021P 2010-12-22 2010-12-22
US61/426,021 2010-12-22

Publications (2)

Publication Number Publication Date
WO2012088247A2 WO2012088247A2 (fr) 2012-06-28
WO2012088247A3 true WO2012088247A3 (fr) 2012-09-20

Family

ID=46314882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/066437 Ceased WO2012088247A2 (fr) 2010-12-22 2011-12-21 Fragments et anticorps anti-c5/c5a/c5adesr

Country Status (2)

Country Link
CA (1) CA2822288A1 (fr)
WO (1) WO2012088247A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (fr) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène, apte à se lier de façon répétée à une pluralité de molécules d'antigène
DK3424953T3 (en) * 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
WO2015021409A1 (fr) * 2013-08-09 2015-02-12 King's College London Compositions et méthodes associées au c5l2
CA2932547C (fr) * 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Modules navettes de barriere hemato-encephalique monovalents
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI873952B (zh) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
EP3494991A4 (fr) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liées à il-8
EP3529619B1 (fr) * 2016-10-19 2021-06-30 Alexion Pharmaceuticals, Inc. Procédé de quantification de c5a non lié dans un échantillon
WO2018075758A1 (fr) * 2016-10-19 2018-04-26 Alexion Pharmaceuticals, Inc. Procédé de quantification de c5 non liée dans un échantillon
SG11201908744PA (en) * 2017-03-23 2019-10-30 Univ Pennsylvania Anti-c5a antibodies and uses thereof
EP3694885A1 (fr) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Anticorps, anticorps activables, anticorps bispécifiques, et anticorps activables bispécifiques et leurs procédés d'utilisation
JP7842564B2 (ja) * 2018-09-21 2026-04-08 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 粘液を透過するのを制限するための合成結合剤
US20220227851A1 (en) * 2019-05-24 2022-07-21 Alexion Pharmaceuticals, Inc. Methods of treating vitiligo using an anti-c5 antibody
JP2022535411A (ja) 2019-06-04 2022-08-08 ラ ファーマシューティカルズ インコーポレイテッド 補体阻害剤による炎症性疾患治療
WO2021259160A1 (fr) * 2020-06-24 2021-12-30 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Anticorps reconnaissant de manière spécifique c5a et leurs utilisations
CN114149501B (zh) * 2020-12-11 2023-05-26 天士力生物医药股份有限公司 抗c5抗体及其应用
CN115925918A (zh) * 2021-07-06 2023-04-07 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用
CN116670288A (zh) * 2021-12-22 2023-08-29 舒泰神（北京）生物制药股份有限公司 一种分离的抗C5a抗体及其制剂与应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058956A2 (fr) * 2000-02-10 2001-08-16 Abbott Laboratories Anticorps de liaison de l'interleukine 18 humaine et procedes de preparation et d'utilisation
US20030099647A1 (en) * 2001-10-05 2003-05-29 Deshpande Rajendra V. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20060286112A1 (en) * 2005-05-16 2006-12-21 Sirid-Aimee Kellermann Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
US20090169562A1 (en) * 2006-06-06 2009-07-02 Mark Throsby Human Binding Molecules Having Killing Activity Against Enterococci and Uses Thereof
US20090286283A1 (en) * 2008-05-16 2009-11-19 Samsung Electronics Co., Ltd. Method and affinity column for purifying proteins
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US20100034809A1 (en) * 2008-08-05 2010-02-11 Novartis Ag Compositions and Methods for Antibodies Targeting Complement Protein C5

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058956A2 (fr) * 2000-02-10 2001-08-16 Abbott Laboratories Anticorps de liaison de l'interleukine 18 humaine et procedes de preparation et d'utilisation
US20030099647A1 (en) * 2001-10-05 2003-05-29 Deshpande Rajendra V. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20060286112A1 (en) * 2005-05-16 2006-12-21 Sirid-Aimee Kellermann Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
US20090169562A1 (en) * 2006-06-06 2009-07-02 Mark Throsby Human Binding Molecules Having Killing Activity Against Enterococci and Uses Thereof
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US20090286283A1 (en) * 2008-05-16 2009-11-19 Samsung Electronics Co., Ltd. Method and affinity column for purifying proteins
US20100034809A1 (en) * 2008-08-05 2010-02-11 Novartis Ag Compositions and Methods for Antibodies Targeting Complement Protein C5

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE UNIPROTKB [online] 4 November 2008 (2008-11-04), retrieved from http://www.uniprot.org/uniprot/B5RTL3 Database accession no. B5RTL3 *
LARRICK ET AL.: "Characterization of Murine Monoclonal Antibodies That Recognize Neutralizing Epitopes on Human C5a.", INFECT LMMUN., vol. 55, no. 8, 1987, pages 1867 - 1872, XP002570405 *
MAHAFFEY ET AL.: "Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) Trial.", CIRCULATION., vol. 108, no. 10, 2003, pages 1176 - 1183 *
RAINARD ET AL.: "Quantification of C5a/C5a(desArg) in bovine plasma, serum and milk.", VET RES., vol. 29, no. 1, 1998, pages 73 - 88 *

Also Published As

Publication number Publication date
WO2012088247A2 (fr) 2012-06-28
CA2822288A1 (fr) 2012-06-28

Similar Documents

Publication Publication Date Title
WO2012088247A3 (fr) Fragments et anticorps anti-c5/c5a/c5adesr
WO2010136311A3 (fr) Compositions et procédés de ciblage de la protéine c3b de complément par des anticorps
WO2013173761A3 (fr) Protéines de liaison à l'antigène st2
WO2013011076A3 (fr) Protéines de liaison à un antigène ayant une liaison accrue à fcrn
WO2013043933A3 (fr) Protéines de liaison à un antigène cd27l
IN2014MN00873A (fr)
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
WO2009081285A3 (fr) Anticorps contre le virus de l'hépatite c
WO2011146514A3 (fr) Isolement rapide d'anticorps monoclonaux à partir d'animaux
MA34004B1 (fr) Protéines de liaison à cd127
WO2011032161A8 (fr) Vaccins dirigés contre les cellules de langerhans
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
PH12013501177A1 (en) TNF-a BINDING PROTEINS
WO2009155180A8 (fr) Anticorps anti-il-6 et leurs utilisations
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
WO2011004028A3 (fr) Agents de liaison à tlr3
WO2012156532A8 (fr) Anticorps anti-her3 humain et leurs utilisations
WO2011092593A3 (fr) Anticorps neutralisant le vih-1 et leurs utilisations
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2012125733A3 (fr) Méthodes de dépistage d'anticorps
MX2025002472A (es) Combinaciones de anticuerpos anti-c5 y usos de las mismas
WO2008098917A3 (fr) Nouveaux anticorps
MX2010001237A (es) Nuevos anticuerpos.
PH12012501884B1 (en) Humanized il-25 antibodies
WO2012091465A3 (fr) Anticorps monoclonaux contre l'amyloïde a du sérum, et cellules d'hybridome les produisant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11850408

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2822288

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013546366

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 11850408

Country of ref document: EP

Kind code of ref document: A2